Summary of COVID-19 vilobelimab studies

1. Vlaar et al., Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

368 patient vilobelimab ICU RCT: 26% lower mortality (p=0.08).
RCT 368 mechanically ventilated COVID-19 patients showing lower mortality with vilobelimab.
Dec 2022, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260022002971, https://c19p.org/vlaar